Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings or view top-rated stocks.

8 brokerages have issued 12 month price targets for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $74.00 to $125.00. On average, they anticipate the company's stock price to reach $110.71 in the next year. This suggests that the stock has a possible downside of 4.2%.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.

Horizon Therapeutics Public's stock was trading at $113.80 at the start of the year. Since then, HZNP stock has increased by 1.6% and is now trading at $115.60.
View the best growth stocks for 2023 here.

Horizon Therapeutics Public saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 20.6% from the August 15th total of 7,860,000 shares. Based on an average daily volume of 2,300,000 shares, the days-to-cover ratio is presently 4.1 days.
View Horizon Therapeutics Public's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our HZNP earnings forecast.

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analysts' expectations of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a trailing twelve-month return on equity of 20.46%. The company's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.07 earnings per share.

ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco NASDAQ Next Gen 100 ETF (QQQJ) and Goldman Sachs Hedge Industry VIP ETF (GVIP).

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.51%), Bluefin Capital Management LLC (0.00%), State Street Corp (2.30%), Maven Securities LTD (0.00%), Renaissance Technologies LLC (1.51%) and Soros Fund Management LLC (1.44%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HZNP stock can currently be purchased for approximately $115.60.

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $26.47 billion and generates $3.63 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.87 on an earnings per share basis.

The company employs 2,115 workers across the globe.

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.